Astellas Promotes Doug Geiger to Vice President, Head of New Therapeutic Areas in Marketing Strategy

NORTHBROOK, Ill., Oct. 27, 2015 /PRNewswire/ -- Astellas recently announced that Doug Geiger has been promoted to the position of vice president, head of New Therapeutic Areas in Marketing Strategy. Geiger will be responsible for delivering global strategic commercial leadership on key initiatives within Astellas' emerging therapeutic areas. He will report to Yukio Matsui, senior vice president and head of Marketing Strategy.

"Doug has been a pivotal strategic commercial leader since joining Astellas in 2008," said Matsui. "He will play an instrumental role as we establish a presence in new therapeutic focus areas such as pain, central nervous system, nephrology and inflammation."

Geiger brings 23 years of experience in the pharmaceutical industry. He joined Astellas in 2008 as director of New Product Planning in the U.S., and helped establish the oncology business unit. Since 2012, Geiger has served as senior director and head of the New Product Planning in the U.S., where he played a vital role in optimizing the commercial potential of Astellas' pipeline.

Prior to Astellas, Geiger held several commercial leadership positions at Abbott Laboratories and TAP Pharmaceuticals in marketing, commercial strategy and global commercial development. 

Geiger earned his Bachelor of Science in finance from the University of Illinois, holds a Master of Science in accounting from DePaul University Kellstadt Graduate School of Business and a Masters in Business Administration from Northwestern University Kellogg School of Management.  

About Astellas
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. For more information on Astellas, please visit our website at www.astellas.us, follow us on Twitter atwww.twitter.com/AstellasUS or like our Facebook page at www.facebook.com/AstellasUS.

Photo - http://photos.prnewswire.com/prnh/20151027/281191 
Logo - http://photos.prnewswire.com/prnh/20140416/84970

 

 

SOURCE Astellas

 

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.